Vanguard Personalized Indexing Management LLC Buys 772 Shares of BridgeBio Pharma, Inc. $BBIO

Vanguard Personalized Indexing Management LLC raised its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 5.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 16,178 shares of the company’s stock after acquiring an additional 772 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in BridgeBio Pharma were worth $699,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Invesco Ltd. raised its holdings in shares of BridgeBio Pharma by 147.0% in the first quarter. Invesco Ltd. now owns 2,206,163 shares of the company’s stock valued at $76,267,000 after buying an additional 1,313,036 shares during the last quarter. Cormorant Asset Management LP increased its position in BridgeBio Pharma by 25.0% in the 1st quarter. Cormorant Asset Management LP now owns 2,000,000 shares of the company’s stock valued at $69,140,000 after acquiring an additional 400,000 shares in the last quarter. Driehaus Capital Management LLC bought a new position in shares of BridgeBio Pharma in the first quarter worth about $51,874,000. Price T Rowe Associates Inc. MD raised its stake in shares of BridgeBio Pharma by 17.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,164,967 shares of the company’s stock worth $40,274,000 after acquiring an additional 173,729 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its position in shares of BridgeBio Pharma by 9.3% during the first quarter. Principal Financial Group Inc. now owns 1,148,292 shares of the company’s stock worth $39,696,000 after purchasing an additional 98,153 shares in the last quarter. Institutional investors own 99.85% of the company’s stock.

Insider Buying and Selling at BridgeBio Pharma

In other news, CEO Neil Kumar sold 40,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 8th. The shares were sold at an average price of $54.78, for a total value of $2,191,200.00. Following the completion of the transaction, the chief executive officer directly owned 855,686 shares in the company, valued at approximately $46,874,479.08. The trade was a 4.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Frank Mccormick sold 74,000 shares of the business’s stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $53.16, for a total value of $3,933,840.00. Following the transaction, the director directly owned 83,275 shares of the company’s stock, valued at approximately $4,426,899. The trade was a 47.05% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 597,913 shares of company stock valued at $29,034,227 over the last ninety days. 18.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Jefferies Financial Group started coverage on BridgeBio Pharma in a report on Monday, July 14th. They set a “buy” rating and a $70.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $70.00 price target on shares of BridgeBio Pharma in a research note on Monday, September 15th. UBS Group raised their price objective on shares of BridgeBio Pharma from $72.00 to $82.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Bank of America upped their target price on shares of BridgeBio Pharma from $50.00 to $54.00 and gave the company a “buy” rating in a research report on Wednesday, June 25th. Finally, Wall Street Zen upgraded BridgeBio Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Sixteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, BridgeBio Pharma presently has a consensus rating of “Moderate Buy” and an average target price of $65.06.

BridgeBio Pharma Stock Up 2.4%

NASDAQ:BBIO opened at $56.26 on Tuesday. BridgeBio Pharma, Inc. has a twelve month low of $21.72 and a twelve month high of $57.49. The firm has a market capitalization of $10.76 billion, a price-to-earnings ratio of -13.76 and a beta of 1.36. The stock’s 50 day moving average price is $52.15 and its two-hundred day moving average price is $43.90.

BridgeBio Pharma (NASDAQ:BBIO) last issued its earnings results on Tuesday, August 5th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.12). The firm had revenue of $110.57 million for the quarter, compared to the consensus estimate of $98.46 million. The business’s revenue for the quarter was up 4999.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.39) earnings per share. As a group, analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current year.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.